This work was supported by grants from National Key Technology R&D Program of China during the llth Five-Year Plan Period (No. 2007BAI05B08) and National Natural Science Foundation of China (No. 30772238).
Background Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor, has shown promising activity in recurrent malignant gliomas. We reported the treatment response for the combination o...